Legend Biotech USA Inc
    Industry / private company
    
    
        Location: 
        Piscataway, NJ,
        
                United States (USA) (US)
                
    
 
        
    
    
    
    
    
    
    
        
    
        
    
        
    
    
    
        
            
                
  
  MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT) (2022)
  Hillengass J, Cohen AD, Delforge M, Einsele H, Goldschmidt H, Weisel K, Raab MS, et al.
  Journal article
            
                
  
  LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022)
  Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, et al.
  Journal article
            
                
  
  Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies (2022)
  Cohen AD, Parekh S, Santomasso BD, Gallego Perez-Larraya J, Van De Donk NWCJ, Arnulf B, Mateos MV, et al.
  Journal article